Stockscreener 앱 받기
27.37
1.12%
-0.31
시간 외 거래:
27.37
전일 마감가:
$27.68
열려 있는:
$27.77
하루 거래량:
1.54M
Relative Volume:
1.11
시가총액:
$2.14B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-36.49
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
+15.78%
1개월 성능:
+2.97%
6개월 성능:
-34.14%
1년 성능:
-8.68%
1일 변동 폭
$27.35
$28.69
1주일 범위
$23.35
$28.69
52주 변동 폭
$22.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
27.37 | 1.88B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Candlestick Signal Suggests Reversal in Veracyte Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Veracyte stock price target lowered to $28 from $29 at Morgan Stanley - Investing.com Nigeria
Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns - TipRanks
Veracyte price target lowered to $28 from $29 at Morgan Stanley - TipRanks
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript - Insider Monkey
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones - TipRanks
Veracyte Receives Buy Rating and $37 Price Target from Guggenheim Analyst - AInvest
Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care - Eastern Progress
Veracyte (VCYT) Q2 Revenue Jumps 14% - AOL.com
Veracyte stock rating reiterated at Outperform by William Blair - Investing.com India
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls - Investing.com Canada
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls By Investing.com - Investing.com South Africa
Veracyte's 2025 Q2 Financial Performance and Strategic Momentum: A Deep Dive into Diagnostic Innovation and Oncology Expansion - AInvest
Veracyte Announces Second Quarter 2025 Financial Results - BioSpace
Veracyte's 2025 Earnings Call: A Catalyst-Driven Path to Sustained Double-Digit Growth and 25%+ Adjusted EBITDA Margins - AInvest
Veracyte Reports Strong Q2 2025 Revenue Growth - TipRanks
Veracyte’s Revenue Growth Outpaces Forecasts And Lifts Guidance - Finimize
Veracyte: Q2 Earnings Snapshot - San Francisco Chronicle
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Veracyte Q2 2025 slides: Decipher drives 14% revenue growth, EBITDA margins expand - Investing.com Nigeria
Veracyte Q2 revenue rises 14%, beats expectations - MarketScreener
Veracyte Inc (VCYT) Q2 2025 Earnings: Revenue Surpasses Estimates at $130.2M, Reports GAAP Net Loss - GuruFocus
Veracyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Veracyte shares surge as Q2 profits quadruple expectations - Investing.com
Veracyte shares surge as Q2 profits quadruple expectations By Investing.com - Investing.com Canada
Veracyte Inc earnings beat by $0.33, revenue topped estimates - Investing.com Canada
Veracyte reports Q2 EPS 44c, consensus 30c - TipRanks
Veracyte sees FY25 revenue $477M-$483M, consensus $491.92M - TipRanks
Earnings Flash (VCYT) Veracyte, Inc. Reports Q2 Revenue $130.2M, vs. FactSet Est of $121.0M - MarketScreener
Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.44 per Share, vs. FactSet Est of $0.26 - MarketScreener
Press Release: Veracyte Announces Second Quarter 2025 Financial Results - 富途牛牛
Veracyte Q2 2025 Earnings Call Transcript - MarketBeat
Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For - Yahoo Finance
What catalysts could drive Veracyte Inc. stock higher in 2025Invest smarter with daily market updates - Jammu Links News
How does Veracyte Inc. compare to its industry peersFree Stock Market Trend Analysis - Jammu Links News
How does Veracyte Inc. generate profit in a changing economyMaximize portfolio growth with strategic plans - Jammu Links News
How many analysts rate Veracyte Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
Should I hold or sell Veracyte Inc. stock in 2025Achieve consistent double-digit growth rates - Jammu Links News
What is the risk reward ratio of investing in Veracyte Inc. stockUnlock exclusive investment alerts - Jammu Links News
How strong is Veracyte Inc. company’s balance sheetOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Veracyte Inc. stockSuperior risk-adjusted returns - Jammu Links News
What drives Veracyte Inc. stock priceUnprecedented market success - Jammu Links News
What institutional investors are buying Veracyte Inc. stockInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Veracyte Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
When is Veracyte Inc. stock expected to show significant growthCapitalize on market momentum for maximum gains - Jammu Links News
What are analysts’ price targets for Veracyte Inc. in the next 12 monthsSuperior trading gains - Jammu Links News
How Veracyte Inc. stock performs during market volatilityStep-by-Step Stock Investment Guide Gains Popularity - beatles.ru
How volatile is Veracyte Inc. stock compared to the marketLow Risk Updates For Beginners - Jammu Links News
Morgan Stanley Downgrades Iridium Communications to Overweight with $37 PT. - AInvest
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):